Purple Biotech Positive Final Results of Phase 2 Study of CM24 in Second Line Pancreatic Cancer

 

• Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints
   
• A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated significant improvement in the treatment arm over the control of 79% reduction in risk of death (HR 0.21, P = 0.04) with median OS improvement of 5.1 months and over 90% reduction in risk of progression or death (HR < 0.1, P = 0.003) with median PFS improvement of 2.9 months and improvement in the treatment arm over the control in ORR of 50% vs. 0%.
  
  
• Phase 2b clinical study is planned in multiple selected indications, potentially targeting patients based on biomarkers  

https://www.globenewswire.com/news-release/2024/12/02/2989659/0/en/Purple-Biotech-Reports-Positive-Final-Results-from-Randomized-Phase-2-Study-of-CM24-in-Second-Line-Pancreatic-Cancer.html